2025
P-1503. Dual β-Lactam Approach for Treatment of Mycobacterium abscessus Infections in Adults – Results in 19 Patients
Kalyatanda G, Dousa K, Lyons H, Mardourian M, Rhodes J, Iakovidis A, El-Helou G, Wilson B, Daley C, Holland S, Kreiswirth B, Nguyen D, Shin E, Kurz S, Johnson J, Bonomo R. P-1503. Dual β-Lactam Approach for Treatment of Mycobacterium abscessus Infections in Adults – Results in 19 Patients. Open Forum Infectious Diseases 2025, 12: ofae631.1672. PMCID: PMC11778049, DOI: 10.1093/ofid/ofae631.1672.Peer-Reviewed Original ResearchSubspecies abscessusB-lactamAssociated with high cure ratesIn vitro susceptibility resultsMulti-drug regimensCurrent treatment regimensSolid organ transplantationHigh cure ratesTime to initiationOptimize treatment outcomesMab infectionSynergy testClinical cureImmunocompromised patientsPulmonary infectionDiscontinued treatmentTreatment regimensCase reportClinical outcomesCure rateImmunocompromised individualsAutoimmune diseasesTreatment successEarly treatmentCulture conversion
2024
Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis.
Wallis R, Sabi I, Lalashowi J, Bakuli A, Mapamba D, Olomi W, Siyame E, Ngaraguza B, Chimbe O, Charalambous S, Rachow A, Ivanova O, Zurba L, Myombe B, Kunambi R, Hoelscher M, Ntinginya N, Churchyard G. Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis. NEJM Evidence 2024, 3: evidoa2300332. PMID: 39189858, DOI: 10.1056/evidoa2300332.Peer-Reviewed Original ResearchConceptsWhole blood glutathione levelsLung functionN-acetylcysteinePulmonary tuberculosisCulture conversionSecondary outcomesGlutathione levelsEffect of N-acetylcysteineTuberculosis treatment outcomesOutcome of lung functionOral N-acetylcysteineRecovery of lung functionAdjunctive N-acetylcysteineAssociated with improved recoveryN-acetylcysteine treatmentPermanent lung injuryFar-advanced tuberculosisSputum cultureStandard therapyNAC administrationAdverse eventsLung injuryGlobal health concernCohort studyClinical evaluation
2023
Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease
Siegel S, Griffith D, Philley J, Brown-Elliott B, Brunton A, Sullivan P, Fuss C, Strnad L, Wallace R, Winthrop K. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease. CHEST Journal 2023, 164: 846-859. PMID: 37419144, PMCID: PMC10645596, DOI: 10.1016/j.chest.2023.05.036.Peer-Reviewed Original ResearchConceptsAmikacin liposome inhalation suspensionAmikacin resistanceCulture conversionInhalation suspensionMycobacterium abscessus lung diseasePresence of macrolide resistanceEnd pointsMicrobiological end pointsMonthly sputum culturesSputum culture conversionTreatment-refractory diseaseOpen-label protocolSecondary end pointsOpen-label trialCohort of patientsCavitary diseaseSputum culturePretreatment isolatesM abscessusOpen-labelOral antimicrobialsParenteral antibioticsCompanion therapyMacrolide resistanceMultidrug therapy
2020
Time to sputum culture conversion and its predictors among patients with multidrug-resistant tuberculosis in Hangzhou, China
Li Q, Lu M, Hsieh E, Wu L, Wu Y, Wang M, Wang L, Zhao G, Xie L, Qian HZ. Time to sputum culture conversion and its predictors among patients with multidrug-resistant tuberculosis in Hangzhou, China. Medicine 2020, 99: e23649. PMID: 33327347, PMCID: PMC7738096, DOI: 10.1097/md.0000000000023649.Peer-Reviewed Original ResearchConceptsInitial sputum culture conversionSputum culture conversionPoor treatment outcomesSuccessful treatment outcomeTreatment outcomesCulture conversionMDR-TBMultidrug-resistant tuberculosis patientsCox proportional hazards regressionMDR-TB treatmentMDR-TB patientsRetrospective cohort studyKaplan-Meier methodTreatment success rateInitiation of treatmentMultidrug-resistant tuberculosisProportional hazards regressionConsecutive negative culturesRisk of transmissionCohort studyTuberculosis patientsTreatment failureHazards regressionOutpatient treatmentInpatient treatmentBedaquiline Adherence Mediates Sputum TB Culture Conversion in MDR/XDR-TB Patients Co-Infected with HIV
Mudd J, Wolf A, Zelnick J, Boodhram R, Orrell C, Daftary A, Friedland G, Padayatchi N, O'Donnell M. Bedaquiline Adherence Mediates Sputum TB Culture Conversion in MDR/XDR-TB Patients Co-Infected with HIV. 2020, a2691-a2691. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2691.Peer-Reviewed Original Research
2016
Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis
Kunkel A, Cobelens FG, Cohen T. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. PLOS Medicine 2016, 13: e1002142. PMID: 27727274, PMCID: PMC5058480, DOI: 10.1371/journal.pmed.1002142.Peer-Reviewed Original ResearchConceptsTreatment of tuberculosisMDR-TB treatmentTB treatmentSecondary casesDrug-resistant (XDR) TBResistance patternsLife expectancyMultidrug-resistant TB patientsDrug bedaquilineMDR-TB drugsAnti-tuberculosis drug bedaquilineCulture conversionMDR patientsTB patientsMortality benefitBedaquiline resistanceMedian timeRisk of resistanceTB drugsDecrease transmissionHypothetical cohortSources of heterogeneityDrug interactionsInitial cohortTime of initiation
2014
Reducing Communication Delays and Improving Quality of Care with a Tuberculosis Laboratory Information System in Resource Poor Environments: A Cluster Randomized Controlled Trial
Blaya J, Shin S, Yagui M, Contreras C, Cegielski P, Yale G, Suarez C, Asencios L, Bayona J, Kim J, Fraser H. Reducing Communication Delays and Improving Quality of Care with a Tuberculosis Laboratory Information System in Resource Poor Environments: A Cluster Randomized Controlled Trial. PLOS ONE 2014, 9: e90110. PMID: 24721980, PMCID: PMC3982951, DOI: 10.1371/journal.pone.0090110.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntitubercular AgentsClinical Laboratory Information SystemsCommunicationDatabases, FactualDeveloping CountriesFemaleHumansLaboratoriesMaleMedical ErrorsMicrobial Sensitivity TestsMiddle AgedPeruPovertyProportional Hazards ModelsProspective StudiesQuality ImprovementQuality of Health CareResearch DesignTreatment OutcomeTuberculosisTuberculosis, Multidrug-ResistantYoung AdultConceptsIntervention health centersHealth centersDrug susceptibility testLaboratory information systemMDR-TB risk factorsMulti-drug resistant tuberculosisMDR-TB patientsPrimary health centersMain outcome measuresCulture convertCulture conversionResistant tuberculosisRisk factorsPatient outcomesClinical impactOutcome measuresDays less timePatientsPatient treatmentStudy designSusceptibility testsBaseline dataTrialsOnly studyTreatment
2013
Chest Radiograph Findings and Time to Culture Conversion in Patients with Multidrug-Resistant Tuberculosis and HIV in Tugela Ferry, South Africa
Brust JC, Berman AR, Zalta B, Haramati LB, Ning Y, Heo M, van der Merwe TL, Bamber S, Moll AP, Friedland GH, Shah NS, Gandhi NR. Chest Radiograph Findings and Time to Culture Conversion in Patients with Multidrug-Resistant Tuberculosis and HIV in Tugela Ferry, South Africa. PLOS ONE 2013, 8: e73975. PMID: 24040132, PMCID: PMC3765317, DOI: 10.1371/journal.pone.0073975.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisBaseline chest radiographSputum smear statusCulture conversionMajority of patientsCD4 countHilar lymphadenopathySmear statusPleural effusionSputum smearChest radiographsAntiretroviral therapy eraCulture conversion rateMedian CD4 countPercent of patientsChest radiograph findingsEnd of treatmentTherapy eraAdvanced immunodeficiencyCavitary diseaseRadiograph findingsHIV statusRadiographic featuresIndependent associationTreatment outcomes
2011
Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa
Brust JC, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, Moll AP, Li X, Loveday M, Bamber SA, Lalloo UG, Friedland GH, Shah NS, Gandhi NR. Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa. PLOS ONE 2011, 6: e15841. PMID: 21253585, PMCID: PMC3017058, DOI: 10.1371/journal.pone.0015841.Peer-Reviewed Original ResearchConceptsMDR-TB patientsCulture conversion rateMDR-TB treatmentMonths of therapyAntiretroviral therapyHIV-coCulture conversionHIV co-infected patientsMultidrug-resistant tuberculosis patientsTiming of ARTMDR-TB therapyCo-infected patientsHIV-negative patientsSecond-line regimenSimilar cure ratesDays of initiationResource-limited settingsHIV prevalentART medicationsCD4 countMDR-TBTuberculosis patientsSputum cultureSuch patientsHIV status
2010
Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa.
Thomas TA, Shenoi SV, Heysell SK, Eksteen FJ, Sunkari VB, Gandhi NR, Friedland G, Shah NS. Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa. The International Journal Of Tuberculosis And Lung Disease 2010, 14: 1244-51. PMID: 20843414, PMCID: PMC3030274.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusXDR-TB diagnosisXDR-TBDrug-resistant tuberculosisPediatric wardImmunodeficiency virusRural South AfricaXDR-TB patientsXDR-TB treatmentActive antiretroviral therapySputum culture conversionNeuropsychiatric side effectsHospital pediatric wardInfection control policiesCulture conversionAntiretroviral therapyRadiographic improvementNosocomial transmissionOverlapping toxicitiesMicrobiologic dataHIV treatmentMedical recordsMicrobiologic diagnosisHIV therapyPrevious history
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply